首页 | 本学科首页   官方微博 | 高级检索  
检索        


Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
Authors:Charlotte C van Ruiten MD  Dick J Veltman MD  PhD  Madelief Wijdeveld MSc  Jennifer S ten Kulve MD  PhD  Mark H H Kramer MD  PhD  Max Nieuwdorp MD  PhD  Richard G IJzerman MD  PhD
Institution:1. Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands;2. Department of Psychiatry, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands;3. Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, The Netherlands

Department of Vascular Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands

Abstract:
Keywords:central regulation of appetite  dapagliflozin  exenatide  functional neuroimaging  GLP-1 receptor agonist  obesity  SGLT2 inhibitor  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号